Key result
Elevated serum miR-6891 independently predicts post-ablation AF recurrence and drives atrial fibroblast dysfunction.
Why the study?
Does serum miR-6891 predict post-ablation recurrence in atrial fibrillation patients and does miR-6891 inhibition prevent Ang II-induced dysfunction in human atrial fibroblasts?
Observational
Does serum miR-6891 predict post-ablation recurrence in atrial fibrillation patients and does miR-6891 inhibition prevent Ang II-induced dysfunction in human atrial fibroblasts?
Serum miR-6891 is an independent predictor of post-ablation atrial fibrillation recurrence and drives atrial fibroblast dysfunction by targeting PTEN, representing a potential biomarker and therapeutic target.
Answers are grounded in this paper and cite their sources.
miR-6891 may predict post-ablation AF recurrence; hypothesis-generating for PTEN-targeted inhibition in fibroblasts.
The molecular mechanisms underlying AF pathogenesis and post‑ablation relapse remain incompletely understood. This study aimed to investigate the expression profile and prognostic value of miR‑6891 in AF, as well as its functional role and downstream mechanism in Ang II‑stimulated atrial fibroblasts. Serum miR‑6891 levels were measured by RT‑qPCR, and its recurrence‑predictive performance was evaluated by ROC curve. Multivariate logistic regression was performed to identify independent risk factors for post‑ablation recurrence. In vitro assays, human atrial fibroblasts were treated with Ang II to mimic pathological remodeling. Cellular migration, proliferation, ferroptosis markers (GSH‑Px, ROS, MDA, Fe²⁺), inflammatory cytokines (TNF‑α, IL‑6, IL‑1β), and fibrosis‑related proteins (Collagen I, MMP9, Collagen III) were assessed. Target prediction and validation were conducted using bioinformatics and dual‑luciferase reporter assays. Functional rescue experiments were performed by co‑transfection with PTEN siRNA. miR‑6891 was significantly upregulated in serum of AF patients compared with controls and exhibited favorable predictive accuracy. Multivariate logistic regression identified miR‑6891 and hs‑CRP as independent predictors of recurrence. In vitro, miR‑6891 inhibition suppressed Ang II‑induced migration, proliferation, ferroptosis, inflammation, and fibrosis. Mechanistically, Ang II downregulated PTEN, an effect reversed by miR‑6891 inhibitor. Silencing PTEN partially abrogated the protective effects of miR‑6891 inhibition on cellular dysfunction, ferroptosis, inflammation, and fibrosis. miR‑6891 is upregulated in AF and serves as a novel candidate independent predictor of post‑ablation recurrence. It mediates Ang II‑induced pathological changes in atrial fibroblasts by directly targeting PTEN, suggesting that miR‑6891 may represent a novel therapeutic target for AF management.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted an observational in Atrial fibrillation. Serum miR-6891 expression / miR-6891 inhibition in vitro vs. Controls (clinical); untreated or PTEN siRNA co-transfected human atrial fibroblasts (in vitro) was evaluated on Post-ablation atrial fibrillation recurrence (clinical); fibroblast migration, proliferation, ferroptosis, inflammation, and fibrosis (in vitro).
Synapse has enriched 10 related papers. Consider them for comparative context: